2616 Stock Overview
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
CStone Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.86 |
| 52 Week High | HK$3.79 |
| 52 Week Low | HK$0.80 |
| Beta | 0.16 |
| 1 Month Change | -15.69% |
| 3 Month Change | -56.12% |
| 1 Year Change | -76.82% |
| 3 Year Change | -90.50% |
| 5 Year Change | -93.76% |
| Change since IPO | -93.31% |
Recent News & Updates
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04
Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18Recent updates
Lacklustre Performance Is Driving CStone Pharmaceuticals' (HKG:2616) 28% Price Drop
Mar 04Benign Growth For CStone Pharmaceuticals (HKG:2616) Underpins Stock's 25% Plummet
Jan 18The Market Doesn't Like What It Sees From CStone Pharmaceuticals' (HKG:2616) Revenues Yet As Shares Tumble 26%
Oct 04Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 03Is CStone Pharmaceuticals (HKG:2616) A Risky Investment?
Oct 20Is CStone Pharmaceuticals (HKG:2616) Using Too Much Debt?
Dec 17Analysts Expect Breakeven For CStone Pharmaceuticals (HKG:2616) Before Long
Apr 29What Kind Of Shareholders Own CStone Pharmaceuticals (HKG:2616)?
Mar 02Shareholder Returns
| 2616 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.3% | -6.1% | -2.8% |
| 1Y | -76.8% | -46.6% | -15.0% |
Return vs Industry: 2616 underperformed the Hong Kong Biotechs industry which returned -47.1% over the past year.
Return vs Market: 2616 underperformed the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
| 2616 volatility | |
|---|---|
| 2616 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 2616's share price has been volatile over the past 3 months.
Volatility Over Time: 2616's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 474 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
CStone Pharmaceuticals Fundamentals Summary
| 2616 fundamental statistics | |
|---|---|
| Market cap | HK$1.10b |
| Earnings (TTM) | -HK$811.83m |
| Revenue (TTM) | HK$520.50m |
2.1x
P/S Ratio-1.3x
P/E RatioIs 2616 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2616 income statement (TTM) | |
|---|---|
| Revenue | CN¥481.07m |
| Cost of Revenue | CN¥218.30m |
| Gross Profit | CN¥262.77m |
| Other Expenses | CN¥1.01b |
| Earnings | -CN¥750.33m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 54.62% |
| Net Profit Margin | -155.97% |
| Debt/Equity Ratio | 28.7% |
How did 2616 perform over the long term?
See historical performance and comparison